
Chronic rhinosinusitis (CRS) carries a significant disease burden that negatively impacts the QoL of patients. Therefore, long-acting, local anti‐inflammatory treatments that improve the QoL of CRS patients are needed. This study found that LYR‐210 (7500μg) significantly improved scores for SNOT‐22 subdomains and SF‐36v2 at week 24.
Like
Save
Share